Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in MPS VII

Ultragenyx announced the dosing of the first patient in the pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003) for the treatment of MPS VII. Read the full press release here.

This entry was posted in News. Bookmark the permalink.

Comments are closed.